MRK250103P108000
- 7.48
- 0.000.00%
Merck & Co Newsroom
FDA Issues First Draft Guidance on Use of AI in Drug, Medical Device Development
Merck to Buy Vaccine Plant From WuXi Biologics: Report
CES Tech Conference Week Starts with Nvidia and Chips Climbing | Live Stock
Citi's Recommended List of Large-cap Stocks: GOOGL, STZ, DAL, and More
MilliporeSigma Acquires HUB Organoids Holding B.V., Expands Next-Gen Biology Portfolio
Express News | RPT-WuXi Biologics - Wuxi Vaccines Ireland to Sell All Property and Assets Related to Vaccines Ireland Facility
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Santa Clause Came and Went Without Bringing Gifts | Weekly Buzz
Friday? More Like Grinch Day | Wall Street Today
Best Income Ideas for 2025: Stocks, Bonds, and Everything in Between
Santa Claus Came Without Rallying the Troops | Live Stock
The 15.92% Average Gain in Inauguration Year: Will Trump's Second Term Echo the Trend?
UK Approves Merck's Hypertension Drug Acquired Via $11 Billion Acceleron Pharma Deal
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
Brand Prescription Drugs to Rise an Average 4.5% in 2025
Dogs Of The Dow: Top 10 High-Yield Stocks Offering Dividends Up To 6.8% In 2025
These Are the Best and Worst Stocks This Year
Market Chatter: Drug Companies to Raise Prices on 250 Branded Drugs in 2025
Express News | UK's Mhra: Sotatercept Approved to Treat Adult Patients With Pulmonary Arterial Hypertension (Pah)
Merck & Co., Inc. (NYSE:MRK) Is a Favorite Amongst Institutional Investors Who Own 79%